Veeva Summit Europe: future-proofed AI set to bolster commercial pharma operations
At the 2025 Veeva Commercial Summit Europe, AI and its role in pharma and the wider life sciences industry was…
19 Nov 2025
New protein manufacturing technologies likely to play key role in “five to ten years”
With complex biologics such as monoclonal antibodies (mAb), antibody-drug conjugates (ADCs) and cell and gene therapies (CGTs) attracting the attention of global big pharma companies, the scope of precision medicine…
14 Nov 2025
Raising the bar: can higher drug spending in the UK deliver for pharma and patients?
Following the creation of the UK’s National Institute for Health and Care Excellence (NICE) in 1999, a cost-effectiveness threshold of £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) was chosen…
13 Nov 2025
Estonia’s digital health DNA: Trust, data, and biotech in focus
With just 1.3 million residents, Estonia’s digital footprint far exceeds its size. When Barack Obama visited Tallinn in 2014, he wryly noted that he “should have called the Estonians” when…
10 Nov 2025
Psychedelics potential set to extend beyond mental health
Psychedelics have a long and rich history in human culture, with archaeologists estimating that humans first started consuming psychoactive mushrooms more than 16,500 years ago. While their roots in culture…
30 Oct 2025
Magazine: Cleanroom chronicles
With tighter regulations around biopharma manufacturing and the emergence of advanced therapies, cleanroom design is being fundamentally reshaped. This month's cover feature examines what innovations regulation and cell and gene…
16 Oct 2025
From Nobel to next-gen: Sweden’s quiet life sciences ascent
Sweden’s place on the frontier of science has a long history, with the capital Stockholm coming to a standstill every year since 1901 in eager anticipation of the Nobel Prize…